BGPT: Author Review: Wei Yan Deep Audit

Fuel Your Discoveries

Low confidence. Please provide more context.

Quick Explanation Copied

What this “Wei Yan Deep Audit” includes (from the provided evidence):

OGM vs prenatal routine testing: high concordance with CMA/karyotyping and a small incremental diagnostic yield in negatives, with important limitations around culture time and low-confidence regions.
First-line ICI outcomes in advanced NSCLC: retrospective, small, heterogeneous real-world cohort; PD-L1 ≥50% associated with longer PFS, while many subgroup differences were underpowered.
NIR-to-visible organic upconverter imaging: reported optoelectronic performance and bench/forearm imaging demonstration, but clinical/in-vivo generalizability remains unproven.

Key evidence anchors:

OGM concordance plot • NSCLC survival summary • OGM yield change

Long Explanation

Wei Yan Deep Audit — Scientific Strength Audit (Evidence-Based)

This audit can only evaluate what is explicitly present in the provided research-data bundle: three paper-level evidence packets (two clinical genetics/oncology cohorts and one biomedical imaging device study). No author profile, publication list, or bibliometrics for “Wei Yan” is included in your input.

1) Visualizations (from provided raw extracted values)

All figures below use only the numeric fields explicitly included in your provided “extracted_data” content.

A. Prenatal OGM (10.1186/s12967-025-06901-9) — Concordance & Yield

The OGM study is a retrospective cohort (Homo sapiens prenatal samples; n=217 total), reporting blinded and unblinded concordance metrics vs CMA and karyotyping, and an incremental diagnostic rate in routine-negative cases. Evidence:

What the numbers support (and what they cannot)

Strength: Reported high concordance under blinded comparison (CMA ~97.8%; KT ~96.4%), and near-perfect agreement after unblinded/manual reanalysis for CMA and KT+CMA metrics.
Strength: A small but explicit incremental detection in routine CMA-negative samples (one additional ~3 kb deletion in FGF8; +1.96% in negatives per the extracted summary).
Limitation: This is still a retrospective cohort with stated constraints: AF culture time, inability to detect some centromeric/telomeric regions, and the reliance on manual review/interpretation for low-confidence regions.

Scientific interpretation caution: The “extra case” improves yield, but without prevalence stratification and without a prospective workflow model (turnaround time, cost, false positive rates, and downstream confirmatory burdens), it is difficult to claim superiority as a first-line test beyond the cohort’s specific inclusion/exclusion and reanalysis rules.

B. First-line ICI in Advanced NSCLC (10.21037/jtd-2025-1409) — Risk Factors & Subgroup Precision

What the NSCLC evidence supports (and why certainty is limited)

Strength: The study reports overall ORR, median PFS and OS, and provides hazard ratios for PD-L1 and selected hematologic markers (NLR, PLR) with stated p-values.
Major limitation: Single-center retrospective design with missing PD-L1 for ~49% of patients, heterogeneity in alteration types, small subgroup sizes, and no centralized radiologic review.

Scientific caution: Associations (e.g., PD-L1 with PFS) may be confounded by baseline prognostic differences and treatment regimen imbalance. Without prospective randomization and with incomplete biomarker availability, hazard ratio patterns should be viewed as hypothesis-generating within the cohort’s context.

C. NIR-to-Visible Organic Upconverter Imaging (10.1038/srep32324) — Device Performance Claims

What this imaging-device evidence supports (and what it doesn’t)

Strength: The paper reports efficiency/voltage improvements with specific electrode/EIL configurations, and includes a bench demonstration of transparent NIR-to-visible mapping for human forearm superficial veins.
Limitation: Bench/limited demonstrations; lack of specified human sample size in the extracted summary; and unclear translation to deeper tissue, long-term stability, and broader clinical imaging conditions.

Scientific caution: Device physics improvements do not automatically imply clinically reliable vascular mapping across skin thickness, motion, and confounders; the evidence supports feasibility for superficial mapping under the described experimental conditions.

2) Scientific strength critique of “Wei Yan Deep Audit” (based on the provided bundle)

2.1 What looks scientifically strong

Use of explicit quantitative endpoints: The provided content includes concordance rates, diagnostic yield changes, hazard ratios, median PFS/OS, and device performance metrics, all mapped to numeric fields that can be plotted without invented values.
Inclusion of limitations (not purely headline results): The provided excerpts explicitly mention key constraints: OGM region coverage/culture time/manual review; NSCLC retrospective missingness/no centralized review; and imaging translation/stability/depth uncertainty.

2.2 Key scientific weaknesses / blind spots (based on provided evidence)

No demonstrated authorship context: Your input does not provide evidence of “Wei Yan” being the author of these papers, nor the content of a “Deep Audit” narrative itself (methods, hypotheses, critique style). Therefore, the audit cannot credibly assign scientific expertise to a specific person from these packets alone.
No bibliometric/citation metrics provided: OpenAlex Author Information is empty (no matches). So author citation metrics cannot be assessed from your input.
(No citation possible because no OpenAlex source was included in the bundle.)
Cross-domain mixing: The provided evidence spans prenatal cytogenomics, NSCLC immuno-oncology, and organic optoelectronics. Without an explicit framework explaining why these belong to the same “Wei Yan Deep Audit,” the synthesis risk is that it becomes a collage rather than a scientifically coherent audit.
Evidence strength is heterogeneous: Two items are clinical retrospective cohorts with specific limitations; one item is an engineering/device demonstration with plausible but incomplete clinical translation. Treating them as equally strong would be epistemically unsound.

2.3 What would disprove/reshape the conclusions?

OGM: Prospective, blinded workflow studies across broader populations showing no yield improvement or showing higher discordance/clinical reclassification burden than reported here.
NSCLC ICI: Independent cohorts showing that PD-L1’s prognostic signal disappears when adjusting for confounders and when biomarker acquisition is complete and standardized.
Upconverter imaging: Demonstrations showing poor stability, insufficient signal-to-noise under varied clinical conditions, or lack of measurable benefit beyond existing imaging approaches.

3) Attribution note (critical epistemic humility)

The provided data do not establish that “Wei Yan” is the author of the cited papers, nor provide any direct text of the “Deep Audit.” Therefore, this response grades only the internal scientific evidence quality visible in the provided bundle, not a person’s full track record.

Optional next step

Run a Science AI agent to iteratively cross-check numeric consistency, extract more from the full-text (if accessible), and strengthen the critique structure.

Feedback:

Updated: March 22, 2026